Evidence for polyclonal T cell activation in murine models of systemic lupus erythematosus.
M. E. Gershwin , Bor-Luen Chiang , B. L. Kotzin , B. L. Kotzin
Journal of Immunology 153 ( 3) 1340 -1351
46
1994
Evidence for polyclonal T cell activation in murine models of systemic lupus erythematosus.
M. E. Gershwin , Bor-Luen Chiang , B. L. Kotzin , B. L. Kotzin
Journal of Immunology 153 ( 3) 1340 -1351
46
1994
Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies
J. R. Brahmer , S. L. Topalian , J. Powderly , I. Wollner
Journal of Clinical Oncology 27 3018 -3018
22
2009
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells.
F. Pan , H. Yu , E. V. Dang , J. Barbi
Science 325 ( 5944) 1142 -1146
345
2009
Phase I/II double-blinded randomized study to determine the tolerability and efficacy of two different doses of lenalidomide (Len) in biochemically relapsed prostate cancer (BRPC) (M0) patients (pts).
D. Keizman , V. J. Sinibaldi , M. A. Carducci , S. R. Denmeade
Journal of Clinical Oncology 28 ( 15_suppl) 4554 -4554
1
2010
Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.
M. Sznol , J. D. Powderly , D. C. Smith , J. R. Brahmer
Journal of Clinical Oncology 28 2506 -2506
75
2010
Absence of coding sequence polymorphism in the serum amyloid P component gene (Sap) in autoimmune New Zealand black mice.
C. G. Drake , S. J. Rozzo , T. J. Vyse , B. L. Kotzin
Mammalian Genome 7 ( 6) 466 -467
5
1996
Bacteriolytic therapy can generate a potent immune response against experimental tumors
N. Agrawal , C. Bettegowda , I. Cheong , J.-F. Geschwind
Proceedings of the National Academy of Sciences of the United States of America 101 ( 42) 15172 -15177
191
2004
Genetic analysis of the NZB contribution to lupus-like autoimmune disease in (NZB x NZW)F1 mice
C. G. Drake , S. K. Babcock , E. Palmer , B. L. Kotzin
Proceedings of the National Academy of Sciences of the United States of America 91 ( 9) 4062 -4066
161
1994
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.
I. V. Litvinov , D. J. Vander Griend , L. Antony , S. Dalrymple
Proceedings of the National Academy of Sciences of the United States of America 103 ( 41) 15085 -15090
90
2006
A randomized, double-blind, phase III trial comparing ipilimumab versus placebo following radiotherapy (RT) in patients (pts) with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel (D).
C. G. Drake , H. I. Scher , W. R. Gerritsen , R. Ezzeddine
Journal of Clinical Oncology 29
7
2011
Design of an open-label randomized phase II trial examining the effect of sequencing of sipuleucel-T and androgen deprivation therapy (ADT) on immune markers in prostate cancer patients with a rising prostate specific antigen (PSA) after primary therapy.
E. S. Antonarakis , A. S. Kibel , D. W. Lin , R. C. Tyler
Journal of Clinical Oncology 29
5
2011
Contributions of Ea(z) and Eb(z) MHC genes to lupus susceptibility in New Zealand mice.
Shozo Izui , Marianne Lemeur , Ed Palmer , Timothy J. Vyse
Journal of Immunology 160 ( 6) 2757 -2766
46
1998
Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.
David F. McDermott , Robert J. Motzer , Michael B. Atkins , Elizabeth R. Plimack
Journal of Clinical Oncology 34 4507 -4507
36
2016
Immunotherapy for Prostate Cancer: Walk, Don't Run
Charles G. Drake
Journal of Clinical Oncology 27 ( 25) 4035 -4037
32
2009
A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).
Lauren Christine Harshman , Maneka Puligandla , Naomi B Haas , Mohamad Allaf
Journal of Clinical Oncology 35
9
2017
Cancer immunotherapy highlights from the 2014 ASCO Meeting.
Lauren C. Harshman , Charles G. Drake , Jennifer A. Wargo , Padmanee Sharma
Cancer immunology research 2 ( 8) 714 -719
34
2014
PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.
Lauren C. Harshman , Charles G. Drake , Toni K. Choueiri
Cancer immunology research 2 ( 12) 1132 -1141
60
2014
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
Andrew B. Sharabi , Christopher J. Nirschl , Christina M. Kochel , Thomas R. Nirschl
Cancer immunology research 3 ( 4) 345 -355
546
2015
A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells
Shu-Han Yu , Qizhi Zheng , David Esopi , Anne Macgregor-Das
Cancer immunology research 3 ( 10) 1175 -1184
31
2015